Whalesbook
GLP-1 Drugs Driving Major Market Shift
The rapid adoption of GLP-1 drugs for weight loss and type 2 diabetes is reshaping the pharmaceutical industry. By mid-to-late 2025, about 12.4% of U.S. adults were using these medications for weight loss, more than doubling from 5.8% in early 2024. Market forecasts predict the global GLP-1 drug market could reach $190 billion by 2035, with the obesity-specific segment alone projected to hit $66.57 billion. This surge, driven by drugs that mimic natural gut hormones to regulate appetite and blood sugar, is one of the fastest drug adoptions seen recently.
Pharma Giants Face Intense Rivalry
Eli Lilly (LLY) and Novo Nordisk (NVO) are leading this market, experiencing significant financial gains alongside intensifying competition. Eli Lilly's tirzepatide-based products, Mounjaro and Zepbound, generated $13.4 billion in Q1 2026, with Mounjaro alone bringing in $8.7 billion. Total sales for Mounjaro and Zepbound reached $36.5 billion in 2025. Eli Lilly's market value is about $931 billion, with a price-to-earnings (P/E) ratio around 35-43. Novo Nordisk's GLP-1 revenue grew 56% to $21.9 billion in 2025. Wegovy contributed $7.1 billion globally, and its new oral semaglutide shows strong early demand. Novo Nordisk's market value is between $152-$200 billion, with a P/E ratio of roughly 11-13, suggesting a more conservative valuation compared to Lilly.
R&D Focus Shifts, Raising 'Bubble' Concerns
The extraordinary success of GLP-1 drugs is reshaping pharmaceutical research and development priorities. Obesity drugs have now overtaken cancer drugs as the biggest driver of the industry's late-stage drug pipeline value, a shift not seen in 16 years, accounting for about 25% of total forecast sales. Projected R&D returns for the industry rose to 7% in 2025, largely due to GLP-1 assets. However, this concentration raises concerns about a potential 'bubble.' If GLP-1 drugs were removed from calculations, industry R&D productivity drops to a much weaker 2.9%. The average cost to develop a drug from discovery to launch has also climbed to $2.67 billion in 2025, increasing the importance of pipeline diversity.
Competition Heats Up on Efficacy and Price
The GLP-1 market is a battleground of intense competition. Eli Lilly's tirzepatide (Mounjaro/Zepbound) has shown greater effectiveness than Novo Nordisk's semaglutide (Ozempic/Wegovy) in some head-to-head comparisons. Lilly's products are outpacing Novo's in global sales. The introduction of oral versions by both companies, including Novo Nordisk's oral Wegovy and Eli Lilly's Foundayo, intensifies this rivalry. Early prescription data shows strong uptake for Novo's oral offering. Pricing pressures are also a growing concern. Eli Lilly anticipates significant effects from pricing reforms in 2026. Novo Nordisk is cutting its U.S. list prices for GLP-1 drugs by an estimated 35%-50% to broaden access and protect its market share.
Supply Chain Issues Ease, Regulatory Focus Grows
Major shortages of GLP-1 drugs have reportedly eased by early 2025 for semaglutide and late 2024 for tirzepatide, though localized supply issues may continue. Past shortages, which emerged in late 2022, were attributed to unexpected demand outstripping production capabilities. The market has also faced scrutiny over compounded GLP-1 products, leading to increased regulatory attention and potential legal actions. This could benefit branded drug manufacturers.
Risks of Over-Concentration
The heavy reliance on GLP-1 drugs creates significant concentration risk for the pharmaceutical sector. This dependence, while currently profitable, exposes companies to a 'bubble' scenario where a downturn in this segment could disproportionately impact overall R&D returns and market valuations. The rising cost of drug development, combined with increasing competition and pricing pressures, further amplifies financial risks. If innovation falters or regulatory challenges arise for GLP-1s, the industry's growth could slow. Eli Lilly's higher valuation multiples (P/E ~35-43) versus Novo Nordisk's (~11-13) suggest investors expect higher future growth from Lilly, increasing the downside risk if these expectations aren't met.
Analyst Views and Future Outlook
Analysts generally remain optimistic, though with varying perspectives. Barclays recently raised Eli Lilly's price target to $1400, citing strong tirzepatide momentum. For Novo Nordisk, analyst ratings are mixed, with a consensus rating of "Hold" from 23 analysts (4 Buy, 18 Hold, 1 Sell). Despite pricing pressures, Eli Lilly has increased its 2026 revenue forecast to $82-$85 billion, projecting a 25% increase. The global GLP-1 market is projected to continue substantial growth, highlighting the ongoing commercial opportunity in managing metabolic diseases.